Follow the Money to These 2 Areas of Unmet Medical Needs


According to the World Health Organization, there are more than 12,000 different diseases and disease-related symptoms that it categorizes. Based on the more than 139,000 clinical studies currently being run worldwide, you'd think we'd have a pretty tight grasp on dealing with the world's most pressing diseases. The reality is that we're not even close, and the evolution of medicine is an ongoing process.

Two areas where this process is still in its infancy -- which can also mean big bucks for investors if they back the correct horse -- is in Alzheimer's and Parkinson's disease research.

Alzheimer's: Where we've been & where we're headed
Based on the 2012 report from the Alzheimer's Association, 5.4 million people in the U.S. have the disease, and it's now become the sixth-leading cause of death. Of the documented cases of demetia, Alzheimer's accounts for about 80% of those cases.

At the moment, our understanding of the disease is minimal at best. One of the few FDA-approved drugs, Amyvid by Eli Lilly , isn't even a treatment at all. It's merely a process-of-elimination test that determines whether beta-amyloid plague markers exist on the brain and allows physicians to determine if a patient is at risk of onset Alzheimer's based on the results. Other Alzheimer drugs are nearing the end of their patent exclusivity come with a long list of side effects.

Other high-profile treatment attempts failed to reach the mark in recent months. Bapineuzumab, an Alzheimer's drug co-developed by Pfizer and Johnson & Johnson , failed in multiple late-stage studies and was eventually shelved. Eli Lilly's solanezumab shared a similar fate, but at least received a partial victory when deeper research noted marginal improvement in patients with mild forms of the disease. Solanezumab is one of three compounds taking part in a long-term international Alzheimer's study.

Given that we've seen seven Alzheimer pipeline drugs die in late-stage trials, the next most-promising one on the docket is Baxter International's IV-administered Gammagard. In mid-stage trials, for those that received the optimal dosing of the drug, Gammagard held the disease at bay for four years. Those patients on the placebo or non-optimal dosing demonstrated a worsening of the disease. The upside is that in optimal dosing, this worked wonders. The downside: This was just a patient pool of 16 people. Late-stage results are due out on Gammagard in the first half of 2013.

As FierceBiotech points out, privately held Lundbeck and EnVivo Pharmaceuticals also have two late-stage Alzheimer's candidates that have shown statistical non-inferiority in trials. However, neither lacks the funding to move their drugs forward and, with a history of failure piling up, it could be difficult to find a partner.

Having spent $200 billion on Alzheimer's care last year, this is clearly a research area that's bound to merit big investment dollars. The question is, can anyone successfully penetrate the blood-brain barrier without a laundry list of side effects?

Parkinson's disease: Where we've been & where we're headed
The Parkinson's Disease Foundation estimates that nearly 1 million people within the U.S. suffer from this neurological disorder, and annual health-care costs of the disease are estimated at $25 billion.

Like Alzheimer's, we're still in the early stages of our understanding of the disease. Sinemet and Sinemet CR, which were both originally developed by Merck , are the most commonly prescribed drugs and are also thought to be the most effective at managing the disease. Unfortunately, long-term use of either drug often leads to decreased motor function. Sinemet is also commonly prescribed as a combination therapy, most notably with Teva Pharamceutical's branded Parkinson's drug, Azilect. However, even this drug combo comes with risks of increased postural hypotension, headaches, joint pain, indigestion, and a load of other cross-drug risks.

The need for even more effective Parkinson's drugs with far fewer side effects is readily apparent. We actually had a chance at gaining another FDA approval last week, however, Impax Laboratories' Rytary (formerly IPX066) received another Complete Response Letter due to manufacturing deficiencies at its Hayward, Calif., facility. We're probably looking at another six months to a year before Rytary makes it back before the FDA.

Beyond Impax, the results haven't been encouraging. Privately held Newron Pharmaceuticals' safinamide is being tested in multiple late-stage studies as an add-on therapy to a dopamine agonist. In its most recent study, which tested a dose of 100mg/day, it proved not statistically significant to the placebo. Similarly, Kyowa Pharmaceuticals' istradefylline failed in multiple small clinical trials.

For now at least, the current Parkinson's treatments look very safe from any added competition, but it's clear based on this disease's prevalence and huge costs that big investment dollars are soon going to be flowing its way.

Can Lilly grow without solanezumab? Find out now!
Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.

The article Follow the Money to These 2 Areas of Unmet Medical Needs originally appeared on

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of, and buying calls on, Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.